Chemotherapy-induced stomatitis and diarrhea

Japanese Journal of Cancer and Chemotherapy

Volumn 38, Issue 11, 2011, Pages 1761-1766

  Kadowaki, Shigenori ^a   Yamaguchi, Kensei ^a  

^a SAITAMA CANCER CENTER   (Japan)

Author keywords

Chemotherapy; Diarrhea; Oral mucositis

Indexed keywords

ANTINEOPLASTIC AGENT; IRINOTECAN; LOPERAMIDE; OCTREOTIDE;

ABDOMINAL PAIN; ARTICLE; CANCER CHEMOTHERAPY; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED DIARRHEA; CHEMOTHERAPY INDUCED STOMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DYSPHAGIA; HUMAN; MOUTH HYGIENE; NEOPLASM; STOMATITIS; TREATMENT OUTCOME;

EID: 84856061110     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Sonis ST, Elting LS, Keefe D, et al: Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(9 Suppl): 1995-2025, 2004. (Pubitemid 38528741)
2. Sonis ST: The pathobiology of mucositis. Nat Rev Cancer 4(4): 277-284, 2004.
3. Logan RM, Stringer AM, Bowen JM, et al: Serum levels of NF-κB and proinflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther 7(7): 1139-1145, 2008.
4. Sonis ST: The biologic role for nuclear factor-κB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med 13(5): 380-389, 2002.
5. Barasch A and Peterson DE: Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol 39(2): 91-100, 2003. (Pubitemid 36050914)
6. Rubenstein EB, Peterson DE, Schubert M, et al: Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9 Suppl): 2026-2046, 2004. (Pubitemid 38525884)
7. Keefe DM, Schubert MM, Elting LS, et al: Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109(5): 820-831, 2007. (Pubitemid 46335677)
8. Sonis ST, Woods PD, White BA, et al: Oral complications of cancer therapies. Pretreatment oral assessment. NCI Monogr 9: 29-32, 1990.
9. Sonis S and Kunz A: Impact of improved dental services on the frequency of oral complications of cancer therapy for patients with non-head-and-neck malignancies. Oral Surg Oral Med Oral Pathol 65(1): 19-22, 1988. (Pubitemid 18044274)
10. Mahood DJ, Dose AM, Loprinzi CL, et al: Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol 9(3): 449-452, 1991.
11. Cascinu S, Fedeli A, Fedeli SL, et al: Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Eur J Cancer B Oral Oncol 30B(4): 234-236, 1994. (Pubitemid 24257732)
12. Rocke LK, Loprinzi CL, Lee JK, et al: A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer 72(7): 2234-2238, 1993. (Pubitemid 23280153)
13. Worthington HV, Clarkson JE, Bryan G, et al: Interventions for preventing oral mucositis for patients with cancer receiving treatment (Review). Cochrane Database Syst Rev CD000978, 2011.
14. Spielberger R, Stiff P, Bensinger W, et al: Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Eng J Med 351(25): 2590-2598, 2004. (Pubitemid 39628580)
15. Stiff PJ, Emmanouilides C, Bensinger WI, et al: Palifermin reduces patients-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 24(33): 5186-5193, 2006. (Pubitemid 46646481)
16. Le QT, Kim HE, Schneider CJ, et al: Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol 29(20): 2808-2814, 2011.
17. Rosen LS, Abdi E, Davis ID, et al: Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 24(33): 5194-5200, 2006. (Pubitemid 46631362)
18. Hensley ML, Hagerty KL, Kewalramani T, et al: American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 27(1): 127-145, 2009.
19. Peterson DE, Jones JB, Petit RG 2nd, et al: Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer 109(2): 322-331, 2007. (Pubitemid 46106247)
20. Peterson DE, Barker NP, Akhmadullina LI, et al: Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. J Clin Oncol 27(26): 4333-4338, 2009.
21. Clarkson JE, Worthington HV, Furness S, et al: Interventions for treating oral mucositis for patients with cancer receiving treatment (Review). Cochrane Database Syst Rev CD001973, 2010.
22. Elting L, Cooksley C, Chambers M, et al: The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98(7): 1531-1539, 2003. (Pubitemid 37151510)
23. Dreizen S, Bodey GP and Valdivieso M: Chemotherapy-associated oral infections in adults with solid tumors. Oral Surg Med Oral Pathol 55(2): 113-120, 1983. (Pubitemid 13163985)
24. Arnold RJ, Gabrail N, Raut M, et al: Clinical implications of chemotherapy-induced diarrhea in patients with cancer. J Support Oncol 3(3): 227-232, 2005. (Pubitemid 40852406)
25. McCollum AD, Catalano PJ, Haller DG, et al: Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst 94(15): 1160-1167, 2002. (Pubitemid 34919053)
26. Zalcberg J, Kerr D, Seymour L, et al: Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. Eur J Cancer 34(12): 1871-1875, 1998. (Pubitemid 28535434)
27. Mercier C and Ciccolini J: Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. Clin Colorectal Cancer 6(4): 288-296, 2006. (Pubitemid 46157478)
28. Takasuna K, Hagiwara T, Hirohashi M, et al: Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol 42(4): 280-286, 1998. (Pubitemid 28393844)
29. Toffoli G, Cecchin E, Corona G, et al: The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24(19): 3061-3068, 2006. (Pubitemid 46638941)
30. Vincenzi B, Schiavon G. Pantano F, et al: Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. Nat Clin Pract Oncol 5(8): 455-465, 2008.
31. Ibrahim NK, Sahin AA, Dubrow RA, et al: Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet 355(9200): 281-283, 2000. (Pubitemid 30068521)
32. Benson AB 3rd, Ajani JA, Catalano RB, et al: Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22(14): 2918-2926, 2004. (Pubitemid 41079912)
33. Abigerges D, Armand JP, Chabot GG, et al: Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86(6): 446-449, 1994. (Pubitemid 24081877)
34. Cascinu S, Bichisao E, Amadori D, et al: High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients. Support Care Cancer 8(1): 65-67, 2000. (Pubitemid 30096549)
35. Cascinu S, Fedeli A, Fedeli SL, et al: Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol 11(1): 148-151, 1993. (Pubitemid 23059987)
36. Barbounis V, Koumakis G, Vassilomanolakis M, et al: Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer 9(4): 258-260, 2001. (Pubitemid 32537284)